Apeiron Enrolls First Patient in Phase 1a/b Study of PRMT5 Inhibitor GTA182 for MTAP-Deleted Solid Tumors
19. November 2024 07:00 ET
|
GT Apeiron LLC
Apeiron Therapeutics (Apeiron), a precision oncology company leveraging state-of-the-art structural biology and AI-guided molecular modeling for drug disco
Turnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
12. November 2024 16:05 ET
|
Turnstone Biologics Corp.
Turnstone reports third quarter 2024 financial results and provides recent business highlights
Oxford BioTherapeutics to Present at World ADC Conference 2024
31. Oktober 2024 08:00 ET
|
Oxford BioTherapeutics
CMO Dr. Harald Haeske to present innovative approaches for combining ADCs with immune checkpoint inhibitors to enhance therapeutic efficacyOBT will also present insights on its target discovery...
Numab Therapeutics Announces Initiation of Phase 1 Clinical Study of NM32 Program in Patients with Solid Tumors
30. Oktober 2024 08:00 ET
|
Numab Therapeutics AG
NM32 is a first-in-class half-life-enhanced T-cell engager targeting ROR1, a tumor associated antigen with broad expression in solid tumors and hematological malignancies Low molecular...
Starget Pharma and Cancer Focus Fund Announce $5.1 Million Investment to Support Phase 1b Clinical Trial of Novel Peptide Radioligand for Precision Cancer Therapy
23. Oktober 2024 07:00 ET
|
Cancer Focus Fund; Starget Pharma
Cancer Focus Fund invested $5.1M in precision peptide radioligand developer Starget for a Phase 1b trial at MD Anderson of its lead theranostic DOTA-PTR-58
Turnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial Runway
11. Oktober 2024 06:00 ET
|
Turnstone Biologics Corp.
Turnstone Biologics announces strategic restructuring to prioritize portfolio and extend financial runway.
ImmunOs Therapeutics AG Raises $11 Million and Further Strengthens Investor Base
17. September 2024 04:00 ET
|
AKAMPION
Existing investors and new investor Double Point Ventures join forces to support ImmunOs TherapeuticsInvestment secures funding of ongoing promising clinical trial of IOS-1002 in solid cancers ...
7 Hills Pharma Safely Doses First Patient in Phase 1b/2a Clinical Trial Testing Alintegimod Against aPD-1-resistant Solid Tumors
03. September 2024 14:02 ET
|
7 Hills Pharma
7 Hills safely doses first cancer patient with alintegimod, a novel selective integrin activator designed to improve the efficacy of checkpoint blockade.
Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer
14. August 2024 16:01 ET
|
Turnstone Biologics Corp.
ORR of 25% and 50% DCR observed in first four evaluable patients treated with TIDAL-01 with advanced CRC
ImmunOs Therapeutics Expands Phase I Clinical Trial of IOS-1002 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Solid Tumors
24. Juli 2024 04:00 ET
|
AKAMPION
Dosing of patients in new combination treatment arm – IOS-1002 plus KEYTRUDA Schlieren (Zurich Area), Switzerland – July 24, 2024 – ImmunOs Therapeutics AG, a biopharmaceutical company using its...